Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.
1. A process for the production of granules containing as an active ingredient imatinib monomethanesulfonate in the alpha crystalline form, said process comprising:
dry granulating an active ingredient consisting of imatinib monomethanesulfonate in the alpha crystalline form and at least one compound acting as a filler-binder to obtain a flowable mixture starting material; and
pressing the starting material to produce the granules;
wherein at least 80% the active ingredient has a mean particle size distribution in the range from 0.01 mm to 1.0 mm; wherein said dry-granulation is carried out in a compactor at pressures in the range from 10 to 300 bar at room temperature; and wherein the resulting granules contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the granules.
2. The process according to claim 1 , wherein in the dry granulation of the starting materials, the latter are pressed with rolls.
3. The process according to claim 1 , wherein the granules contain the active ingredient in a proportion of 30% by weight to 80% by weight, based on the total weight of the granules.
4. The process according to claim 1 , wherein the at least one compound acting as filler-binder comprises a water content in the range from 0.5% by weight to 10.0% by weight, based on the total weight of the filler-binder.
5. The process according to claim 1 , wherein the filler-binder is selected from the group consisting of sugars, sugar alcohols, polymeric glycosides, starches of different origins and inorganic salts.
6. The process according to claim 1 , wherein the filler-binder is selected from the group consisting of modified starches, modified cellulose, modified sugars, modified sugar alcohols, modified lactose, gelatin, gum arabic, gelatinized starch, povidones, and hydroxy-povidone.
7. The process according to claim 1 , wherein the filler-binder is present in concentrations of 75% by weight to 20% by weight, based on the total weight of the granules in addition to the active ingredient present, the sum of the active ingredient and the filler-binder present being 100% by weight.
8. The process according to claim 1 , wherein the granules-contain other additives selected from the group consisting of: disintegrants, flow regulators, mould lubricants, and mould release agents.
9. The process according to claim 1 , wherein said granules are provided with a film coating.
10. The process according to claim 1 , wherein the granules are filled into a sachet or a hard gelatin capsule as a dosage unit, and the amount of active ingredient per dosage unit is in each case about 50 mg to about 1000 mg.